Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ARF like GTPase 2 binding protein pseudogene 4 (ARL2BPP4) is a human genomic sequence classified as a pseudogene, meaning it is derived from the parent ARL2BP gene but does not encode a functional protein. ARL2BPP4 does not perform known biological functions and is not considered a therapeutic target or biomarker. Its parent gene, ARL2BP, encodes a protein that interacts with ARL2 and plays a role in cilia function and is associated with retinitis pigmentosa, but ARL2BPP4 itself lacks coding potential and functional relevance[4][5][11]. Key clarification: If your interest is in molecular functions, disease roles, or drug interactions, refer to the protein-coding gene "ARF like GTPase 2 binding protein" (ARL2BP), not "ARF like GTPase 2 binding protein pseudogene 4" (ARL2BPP4)[3][6][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ARF like GTPase 2 binding protein pseudogene 4 (ARL2BPP4).